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Abstract 
Background: Although smoking and HPV infection are recognized as important risk factors for 
oropharyngeal cancer, how their joint exposure impacts on oropharyngeal cancer risk is unclear. 
Specifically, whether smoking confers any additional risk to HPV-positive oropharyngeal cancer is 
not understood.  
Methods: Using HPV serology as a marker of HPV-related cancer, we examined the interaction 
between smoking and HPV16 in 459 oropharyngeal (and 1445 oral cavity and laryngeal) cancer 
patients and 3024 control participants from two large European multi-centre studies. Odds ratios 
and credible intervals [CrI], adjusted for potential confounders, were estimated using Bayesian 
logistic regression.  
Results: Both smoking [odds ratio (OR [CrI]: 6.82 [4.52, 10.29]) and HPV seropositivity (OR 
[CrI]: 235.69 [99.95, 555.74]) were independently associated with oropharyngeal cancer. The joint 
association of smoking and HPV seropositivity was consistent with that expected on the additive 
scale (synergy index [CrI]: 1.32 [0.51, 3.45]), suggesting they act as independent risk factors for 
oropharyngeal cancer.  
Conclusions: Smoking was consistently associated with increase in oropharyngeal cancer risk in 
models stratified by HPV16 seropositivity. In addition, we report that the prevalence of 
oropharyngeal cancer increases with smoking for both HPV16-positive and HPV16-negative 
persons. The impact of smoking on HPV16-positive oropharyngeal cancer highlights the continued 
need for smoking cessation programmes for primary prevention of head and neck cancer.  
Keywords: Human papillomavirus, tobacco smoking, interaction, head and neck cancer risk, 
oropharynx cancer 
Key Messages 
 The incremental risk due to smoking in HPV16-positive oropharyngeal cancer (if any) 
remains unclear. 
 Pooling two large HNC studies with HPV serology data, we examined the relationship 
between these risk factors. 
 We demonstrated that smoking was consistently associated with increased risk of 
oropharyngeal cancer regardless of HPV status. 
 These data demonstrate that tobacco exposure remains an important risk factor for 
oropharyngeal cancer irrespective of HPV status. 
Introduction 
It is estimated that nearly 600 000 new cancers of the oral cavity, pharynx and larynx are diagnosed 
each year worldwide, contributing to approximately 325 000 deaths each year. 1 Collectively 
referred to as head and neck cancers (HNC), most are squamous cell in origin and are grouped 
together due to aetiological similarities. 2 Nearly 33% of HNC are attributed to smoking alone, 
alcohol alone is estimated to cause nearly 4%, and the largest proportion of cases are attributed to 
the joint exposure to smoking and alcohol, nearly 35%. 3,4 Recently, infection by human 
papillomavirus (HPV) has been associated with a subset of HNC arising at the base of tongue, the 
tonsils and the oropharynx. 5,6 
HPV-positive oropharyngeal carcinoma (OPC) patients tend to be more often never smokers 
compared with HPV-negative patients. 7,8 In addition, statistically non-significant associations 
between smoking and HPV-positive OPC have led to the speculation that smoking is not an 
important risk factor for HPV-positive OPC. 9 However, it is noteworthy that up to 30% of HPV-
positive HNC occur among heavy smokers and alcohol drinkers. 8,10 Furthermore, previous 
analyses did not account for differing baseline risks by HPV status when interpreting the odds ratios 
(OR) for smoking. In addition, classification of HPV status has been an important challenge in such 
studies. We have previously demonstrated that circulating antibodies against HPV16 oncoprotein 
E6 constitute a highly specific marker of HPV16-related OPC, present in nearly 30% of OPC and 
less than 1% of controls, 11,12 whereas antibodies against HPV16 capsid protein L1 are regarded as 
markers of past exposure. 13,14 The rarity of OPC and the limited proportion of never smokers 
necessitate large pooled analysis to examine the relationships between these risk factors.  
A significant proportion of OPC patients report a history of smoking at diagnosis (nearly 80% in the 
USA and European Union); 3,4,8,15 therefore we examined whether smoking increases the risk of 
HPV16-positive OPC. Further, we examined the impact of smoking on the prevalence of OPC 
among HPV-positive and -negative persons. We also examined the association between smoking, 
alcohol intake, HPV16 and the risk of non-oropharyngeal HNC.  
Materials and Methods 
Study sample 
This analysis included two studies of HPV serology and HNC, the Alcohol-Related Cancers and 
Genetic Susceptibility in Europe (ARCAGE) study and the HNC case-control study nested within 
the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort. Briefly, the 
ARCAGE study was conducted during 2002–05 and included 1292 pathologically confirmed 
primary HNC and 1425 controls frequency-matched for age, sex and area of residence. 11,16 Ever 
smokers were defined as individuals who smoked any tobacco product at least once a week for 1 
year, and ever drinkers were those who reported ever consuming any alcoholic beverage. 17 The 
EPIC cohort recruited 521 330 individuals during 1992 and 2000, of whom 385 747 participants 
contributed a blood sample. 18 This analysis included 612 incident HNC and 1599 controls. 12 Two 
controls (one in Denmark) were randomly selected for each cancer patient from appropriate risk sets 
consisting of all cohort participants alive and free of cancer (except non-melanoma skin cancer) at 
the time of diagnosis of the index case. Controls were matched on country, sex, date of blood 
collection (1 month, relaxed to 5 months for sets without available controls) and date of birth (1 
year, relaxed to 5 years for sets without available participants). Ever smokers were individuals who 
reported ever smoking any tobacco product in their lifetime, and ever drinkers were individuals who 
reported ever consuming any alcoholic beverage. HNC included cancers arising at the oral cavity 
(International Classification of Diseases for Oncology (ICD-O) C00.3–C00.9, C02.0–C06.9, 
C14.0–C14.9, excluding C02.4, C02.8, C02.9, C05.1, C05.2, C05.8, C05.9), oropharynx (ICD-O: 
C01, C02.4, C05.1–C05.2, C09, C10), hypopharynx and larynx (ICD-O: C13, C32) and non-
specified and overlapping sites (ICD-O: C02.8, C02.9, C05.8, C05.9, C32.8). Lymphomas were not 
included, and salivary gland cancers were omitted. This analysis included head and neck cancers of 
all histological subtypes, of which squamous cancers comprised the vast majority (∼ 91%), and 
some other rarer non-squamous histologies (6%, in ARCAGE and 9% in EPIC). Informed consent 
was obtained from all participants in both the studies, and the studies were approved by the ethical 
review boards at the participating centres and the International Agency for Research on Cancer.  
HPV serology 
HPV antibodies were assayed using the bead-based multiplex serology method as described 
elsewhere. 19 Testing was performed blind to the case-control status of the participants. Mean 
fluorescence intensity (MFI) values were dichotomized by applying thresholds derived from a 
cross-sectional study among Korean students of mean plus 5 standard deviations (SD; for HPV16 
E6) or the mean plus 3 SD excluding positive outliers (for HPV16 L1), 20 as described previously. 
11,12 
Statistical analysis 
The overall associations between HPV16 (L1 and E6), smoking, alcohol intake and HNC risk were 
assessed by calculating odds ratios (ORs)and their corresponding 95% confidence intervals 
(CIs).These models included age, sex, smoking status (never, former, current), alcohol consumption 
(never, ever plus ethanol g/day at recruitment) and country as covariates. Since certain 
combinations of exposures were very rare (e.g. HPV16 E6-positive never smoking control 
subjects), Bayesian logistic regression models were used to calculate ORs and corresponding 95% 
credible intervals (CrI). These models use a prior distribution to shrink or penalize the regression 
coefficients, thus providing more stable estimates than maximum likelihood methods. Following 
Gelman et al. , 21 all regression inputs were centred, and continuous inputs were re-scaled to have a 
standard deviation of 0.5. All regression coefficients were then modelled with a weakly informative 
Cauchy prior distribution with mean 0 and scale 2.5, with the exception of the intercept, which was 
given a weaker Cauchy prior with scale 10. These models were fitted using the bayesglm function 
in the R package ARM. 21,22 In these analyses, former and current smokers were combined as ever 
smokers and given the few participants who reported never consumption of any alcoholic beverage; 
individuals who consumed 7 g or less of ethanol (equivalent of half a drink) per day were 
considered the reference. Since the results from ARCAGE and EPIC studies were similar, data were 
pooled in order to obtain more precise estimates. Interactions between smoking, alcohol intake and 
HPV16 were examined by the inclusion of an interaction term in the penalized regression models. 
Additive interactions were evaluated by estimating the synergy index (SI). 23 The prevalence of 
OPC by categories of smoking and HPV16 were calculated based on the ORs from the fitted models 
and assumed population prevalence of 0.003, based on the cumulative risk for pharyngeal cancer 
among men and women combined, in more developed regions of the world. 24 All statistical 
analyses were performed using Stata version 11.2 (StataCorp, College Station, TX, USA) and R 
version3.1.0. 25 
Results 
Study profile 
A total of 1904 HNC patients included 459 OPC, 1445 non-oropharyngeal HNC and 3024 control 
subjects. Of these, 1292 HNC cases and 1425 controls were from the ARCAGE study and 612 
HNC cases and 1599 controls from the EPIC study. OPC patients were similar to HNC patients, as 
they tended to be more often men, current smokers and current drinkers ( Table 1 ).  
Main effects of smoking, alcohol consumption and HPV antibodies in OPC 
HPV16 E6-positivity was observed in 0.7% of 3024 controls and 31.6% of 459 OPC subjects, and 
was strongly associated with OPC risk [OR (95% CI): 147.31 (83.07, 361.24)]. The odds of OPC 
was higher among current smokers compared with never smokers [OR (95% CI): 5.34 (3.89, 7.33)]. 
Consumption of ≥ 28 g of ethanol per day (two or more drinks per day) was also associated with 
increased risk of OPC [OR (95% CI): 2.43 (1.77, 3.33)] ( Figure I ).  
Combined effects of smoking and HPV16 in OPC 
To understand the combined effects of smoking and HPV16 in OPC, we examined the relative odds 
of OPC given smoking and HPV16 status ( Table 2 ). Compared with HPV16 E6-negative never 
smokers, ever smoking was associated with 6.82 times increased OPC risk (95% CrI: 4.52, 10.29), 
whereas HPV16 E6-positivity alone was associated with 235.69 times increased odds (95% CrI: 
99.95, 555.74). HPV16 E6-positive ever smokers had 355.82 timeshigher OPC risk (95% CrI: 
177.0, 715.30) compared with individuals negative for both risk factors. HPV16 E6-positivity and 
smoking appeared to interact on a less than multiplicative scale (OR [95% CrI] for the interaction 
term: 0.22 [0.08, 0.62]). The SI for the interaction was calculated to be 1.32 [95% CrI: 0.51, 3.45], 
suggesting that the risks associated with HPV16 E6 and smoking might be additive. Interestingly, 
similar results were observed when HPV16 L1-positivity was examined (OR [95% CrI] for the 
multiplicative interaction term: 0.23 [0.13, 0.43], SI [95% CrI]: 0.75 [0.51, 1.12]) ( Table 2 ). These 
results remained unchanged when analyses were restricted to squamous cell cancers of the 
oropharynx ( Supplementary table V , available as Supplementary data at IJE online). In models 
stratified by HPV status ( Supplementary table I , model 1, available as Supplementary data at IJE 
online), we observed that OPC risk increased with the number of cigarettes smoked per day (CPD) 
among HPV16 L1-negatives (OR [95% CrI] for > 15 CPD: 8.71 [6.01, 12.64]), as well as HPV16 
E6-negatives (OR [95% CrI] for > 15 CPD: 10.69 [7.06, 16.20]). Among HPV16-positives, we 
observed no additional increase in OPC risk with smoking dose ( Supplementary Table I , model 1). 
The limited proportion of HPV16-positive controls in these comparisons is noteworthy; whereas 
2.5% of HPV16 L1-positive controls reported smoking > 15 CPD, this proportion was down to only 
0.2% among HPV16 E6-positives ( Supplementary Table I , model 2). Our previous analysis of 
predictors of HPV16 E6-positivity among cancer-free individuals suggested that the possibility of 
an underlying undiagnosed cancer cannot be ruled out in such subjects. 26 Therefore, we excluded 
all HPV16 E6-positive controls under the assumption that they could be false positives or harbour 
other undiagnosed HPV-related cancer. We then compared HPV16 E6-positive cases with HPV16 
E6-negative controls, to clarify whether smoking might confer any further risk in HPV16-positive 
OPC ( Table 3 ). Results indicate that the OPC risk among HPV16-positive persons increased with 
smoking. Compared with never smokers, both former smokers (OR [95% CrI]: 1.49 [0.95,2.36]) 
and current smokers (OR [95% CrI]: 1.86 [1.17,2.96]) were at increased OPC risk. However, we 
observed a modest trend toward increased OPC risk with smoking dose (OR [95% CrI] for ≤ 15 
CPD: 1.61 [1.03, 2.54] and OR [95% CrI] for > 15 CPD: 1.77 [1.11, 2.84]).  
Relatedly, the relationship between smoking and the risk of HPV-positivity remains poorly 
understood. It remains unclear whether smoking may enhance HPV exposure and/or infection. 
Using HPV seropositivity as the endpoint, Kelsey et al. have recently demonstrated that younger 
smokers are more likely to be seropositive for HPV16 L1 than older smokers. 27 We sought to 
understand whether any age-dependent association existed between smoking and HPV 
seropositivity in this study. Briefly, in analysis restricted to controls, age was divided into tertiles as 
young (< 54), intermediate (54–62) and old (> 62 years of age) subjects. We then examined the 
association between these age categories and HPV16 seropositivity by smoking status. Overall, age 
did not appear to be strongly associated with HPV seropositivity, either HPV16 L1 (OR [95% CI]: 
0.78 [0.56, 1.09]) or HPV16 E6 (OR [95% CI]: 0.67 [0.22, 2.02]), albeit based on small numbers. 
Current smoking, on the other hand, modestly reduced the risk of HPV16 L1 seropositivity (OR 
[95% CI]: 0.79 [0.62, 1.00]) but not HPV16 E6 (OR [95% CI]: 1.00 [0.67, 1.51]) ( Supplementary 
Table VI , available as Supplementary data at IJE online). We found no evidence for an interaction 
between age and smoking towards HPV16 seropositivity ( Supplementary Table VII , available as 
Supplementary data at IJE online). Similarly, when stratified by smoking, age was not associated 
with risk of HPV16 L1 seropositivity in former (OR [95% CI]: 0.91 [0.56, 1.48]) or current 
smokers (OR [95% CI]: 1.36 [0.79, 2.36]) ( Supplementary Table VIII , available as Supplementary 
data at IJE online).  
OPC prevalence by smoking and HPV16 status 
In order to provide a simple appreciation of the joint importance of HPV infection and tobacco 
smoking, we estimated the prevalence of OPC given smoking and HPV16 E6 status, assuming an 
overall OPC population prevalence of 0.003. OPC prevalence among HPV16 E6-negative never 
smokers was negligible (0.05%; 95% CrI: 0.03%, 0.07%), which increased to 0.13% (95% CrI: 
0.08%, 0.20%) in former smokers, and further increased to 0.54% (95% CrI: 0.36%, 0.80%) in 
current smokers. Similarly, among HPV16-positive participants, the baseline prevalence in never 
smokers was 8.94% (95% CrI: 4.20%, 18.01%), 11.58% (95% CrI: 5.38%, 23.19%) in former 
smokers, and further increased to 17.68% (95% CrI: 7.29%, 36.95%) in current smokers ( Figure 2 
).  
Non-oropharyngeal HNC risk factors 
For non-oropharyngeal HNC, current smoking (OR (95% CI): 6.82 (5.51, 8.44)), alcohol 
consumption of > 28 g per day (OR (95% CI): 2.31 (1.87, 2.85)) and HPV16 E6-positivity were 
associated with increased risk for non-oropharyngeal HNC (OR (95%CI): 2.57 (1.24, 5.33)), 
whereas HPV16 L1-positivity was not (OR (95% CI): 1.05 (0.82, 1.35)) ( Supplementary Figure I , 
available as Supplementary data at IJE online). No interaction was observed between HPV16 and 
smoking for non-oropharyngeal HNC ( Supplementary Table II , available as Supplementary data at 
IJE online). Alcohol consumption and HPV16 antibody status did not appear to interact to affect 
risk of either oropharyngeal or non-oropharyngeal HNC ( Supplementary Tables III and 
Supplementary Data , available as Supplementary data at IJE online). Study-specific associations 
between smoking, alcohol intake, HPV16 and OPC risk and non-oropharyngeal HNC risk are 
presented in Supplementary Figures II-V , (available as Supplementary data at IJE online).  
Discussion 
This study supports the notion that smoking and alcohol are important risk factors for all HNC 
subsites, and HPV16 infection is relevant at the oropharynx. We demonstrate that smoking 
increases the risk of OPC, irrespective of HPV16 status. Importantly, OPC remains higher in 
smokers compared with never smokers, among both HPV16-positive and -negative persons. 
The manner in which two (or more) distinct risk factors interact to influence disease risk can be 
tested by examining the joint effects. Biologically, components (or exposures) that lie within the 
same causal pathway are thought to interact, implying that disease will not occur (or will occur at 
the population baseline rates) in the absence of any one of the exposures. Statistically, the combined 
effect may be quantified on the multiplicative or additive scale. Most risk factors interact in greater 
than a multiplicative scale. For example, whereas smoking and alcohol consumption are each 
associated with substantially increased risks of HNC, smokers who also consume alcohol 
experience risk far greater risk than the product of the two. 3,4 Such a ‘supermultiplicative’ risk is 
often interpreted to indicate that the risk factors potentiate the carcinogenic effects of each other. 
Truly additive effects, where the combined risk is similar to the sum of individual risks, are rare. 
Such additive interactions are thought to indicate independence of risk factors. In this study we 
observe that the joint effect of HPV16 (L1 and E6 antibody status) and smoking are consistent with 
that expected on the additive scale. This result suggests that HPV16 and smoking are independent 
risk factors for OPC, a conclusion supported by previous studies. 7,9,28–30 However, that the 
association of smoking with risk of OPC in HPV16-positives has not been statistically significant 
has been interpreted as the absence of risk due to smoking, and has led to the speculation that 
presence of HPV16 could protect against the adverse effects of smoking. 9 In this study, we clearly 
demonstrate that the OPC risk increases with smoking even in the context of HPV16-positive OPC. 
The consistency of these observations when considering HPV16 L1- or HPV16 E6-positivity as 
markers of HPV16 status further strengthens our conclusions. These results would also seem to 
suggest that smoking may induce molecular changes in HPV16-positive OPC. This hypothesis is 
supported by results from the Radiation Therapy Oncology Group (RTOG) trial where OPC 
patients were stratified into three distinct risk-of-death groups; HPV-positive never smokers 
experienced the best prognosis and HPV-negative smokers the worst, and the combined presence of 
smoking and HPV constituted an ‘intermediate’ risk group. 31 
Unlike the recently published report, 27 we found no evidence for an interaction between age and 
smoking in the risk of HPV seropositivity. This largely implies that age is not associated with HPV 
seropositivity regardless of smoking status. Conversely, the association between smoking and HPV 
seropositivity, for either L1 or E6, does not appear to vary with age in this study. In other words, 
smoking did not appear to alter either exposure or infection to HPV16 (L1 and E6, respectively) 
differentially by age in this study.  
Further, our data emphasize that it remains critical to interpret relative risks in the context of the 
dramatically differing baseline risks between HPV16-positive and -negative people. We estimated 
the absolute difference in OPC prevalence between never and current smokers to be 0.5% in HPV16 
E6-negative individual and 8.8% in HPV16 E6-positives, re-emphasizing the importance of 
smoking regardless of HPV16 status. These data suggest that smoking remains an important risk 
factor for OPC, at least in Europe where almost a quarter of the patients are both HPV16 positive 
and report smoking history at diagnosis. In this study, we did not observe a strong interaction 
between alcohol consumption and HPV16. This is perhaps unsurprising given that alcohol appears 
to affect HNC risk at higher doses and primarily in the presence of tobacco smoking. 3,4 
To the best of our knowledge, this constitutes the largest study examining the joint effects of 
smoking and HPV16 infection in OPC. It is important to note that antibody status is a systemic 
marker, and might therefore reflect infection in any location in the body rather than an 
oropharyngeal infection specifically. However, we and others have previously demonstrated HPV16 
E6 to be a highly specific 11,12,28–31 and likely sensitive marker for HPV16-related OPC. 11,12 
Since this uncertainty applies to both cases and controls, it is not expected to lead to biased 
comparisons. Further, self-reported data on alcohol and tobacco use were used and thus may 
contribute to some measurement error, especially in the retrospective case-control study.  
In summary, these results indicate that smoking and HPV16 follow independent pathways towards 
OPC. The impact of smoking on HPV16-positive OPC may have important implications for 
treatment, survival and recurrence of OPC and re-emphasizes the continuing need for tobacco 
cessation programmes. 
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